Skip to Content
Morningstar

Intellia Therapeutics Inc NTLA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$30.28 −0.64 (2.07%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock Our Analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Intellia Earnings: Gene Editing Pipeline Continues to Make Progress; Shares Very Undervalued

Rachel Elfman

Intellia Therapeutics reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. Collaboration revenue totaled $12 million for the quarter, and we appreciate that Intellia ended the quarter in a healthy financial position with about $992 million in cash and marketable securities, which will help fund its R&D expenses as it develops its pipeline candidates. We maintain our positive outlook and fair value estimate of $85 per share. We view the stock as very undervalued, currently trading in 5-star territory, about 70% below our fair value estimate.

Read Full Report

Price vs Fair Value

View History
NTLA is trading at a 64% discount.
Price
$30.93
Fair Value
$88.00
Uncertainty
Very High
1-Star Price
$491.55
5-Star Price
$23.60
Economic Moat
Tzx
Capital Allocation
Kvfszxfll

Bulls Say, Bears Say

Bulls

Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Intellia's pipeline is largely in the early stages of development and several years away from potentially receiving approval.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTLA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$30.92
Day Range
$30.07–31.73
52-Week Range
$22.70–51.93
Bid/Ask
$30.23 / $30.26
Market Cap
$2.71 Bil
Volume/Avg
556,674 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
51.67
Dividend Yield
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
598
Website
https://www.intelliatx.com

Competitors

Valuation

View More
Metric
NTLA
BNTX
MRNA
Price/Earnings (Normalized)
 —7.9329.41
Price/Book Value
 2.661.122.24
Price/Sales
 51.673.403.37
Price/Cash Flow
 —51.47—
Price/Earnings
NTLA
BNTX
MRNA

Financial Strength

Metric
NTLA
BNTX
MRNA
Quick Ratio
 9.379.992.22
Current Ratio
 9.7210.372.46
Interest Coverage
 —877.79−64.76
Quick Ratio
NTLA
BNTX
MRNA

Profitability

Metric
NTLA
BNTX
MRNA
Return on Assets (Normalized)
 −25.29%12.85%−13.62%
Return on Equity (Normalized)
 −30.89%14.68%−18.51%
Return on Invested Capital (Normalized)
 −31.39%13.50%−18.82%
Return on Assets
NTLA
BNTX
MRNA

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZlrdd$453.9 Bil
VRTX
Vertex Pharmaceuticals IncBqrlkrc$90.4 Bil
REGN
Regeneron Pharmaceuticals IncRwmxdy$88.1 Bil
SGEN
Seagen Inc Ordinary SharesYydygg$40.3 Bil
MRNA
Moderna IncRkxw$30.1 Bil
ARGX
argenx SE ADRGxd$26.1 Bil
BNTX
BioNTech SE ADRJcntf$23.6 Bil
ALNY
Alnylam Pharmaceuticals IncRptrp$20.6 Bil
BMRN
Biomarin Pharmaceutical IncXbcfnzr$16.9 Bil
INCY
Incyte CorpDmylgkr$12.0 Bil